MARKERS AND THERAPEUTIC INDICATORS FOR GLIOBLASTOMA MULTIFORME (GBM)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Dec 23, 2016
filing date -
Jun 26, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A signature of proteins occurring in glioblastoma multiforme (GBM) tissue comprised of 33 cell surface proteins (GBMSig) that distinguish subjects with GBM from healthy controls with more than 98% accuracy is described. In addition, four of the members of this signature are particularly useful as blood-borne markers of GBM. Certain other members of the signature are indicators of the possible efficacy of the use of TGF-β1 inhibitors in the treatment of this condition. Methods to treat and to stratify GBM based on GBMSig proteins are also disclosed.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully